Research Article

HPLC-DAD Analysis, Antileishmanial, Antiproliferative, and Antibacterial Activities of *Lacistema pubescens*: An Amazonian Medicinal Plant

Josiane Mello da Silva,¹ Luciana Maria Ribeiro Antinarelli,²
Nícolás de Castro Campos Pinto,¹ Elaine Soares Coimbra,²
Elaine Maria de Souza-Fagundes,³ Antônia Ribeiro,¹ and Elita Scio¹

¹ Bioactive Natural Products Laboratory, Department of Biochemistry, Biological Sciences Institute, Federal University of Juiz de Fora, José Lourenço Kelmer, s/n, São Pedro, 36036-900 Juiz de Fora, MG, Brazil

² Department of Parasitology, Microbiology and Immunology, Biological Sciences Institute, Federal University of Juiz de Fora, Juiz de Fora, MG, Brazil

³ Department of Physiology and Biophysics, Biological Sciences Institute, Federal University of Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha, 31270-901 Belo Horizonte, MG, Brazil

Correspondence should be addressed to Elita Scio; elita.scio@uff.edu.br

Received 13 February 2014; Revised 27 June 2014; Accepted 17 July 2014; Published 7 August 2014

Academic Editor: Fátima Ribeiro-Dias

Copyright © 2014 Josiane Mello da Silva et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Species of the genus *Lacistema* are traditionally used by Brazilian and Peruvian indigenous communities. The present study investigated the *in vitro* antileishmanial activity against several *Leishmania* species, cytotoxicity in murine peritoneal macrophages, antiproliferative activity against HL60 and Jurkat cells, and antibacterial activities against seven bacteria strains of the aerial parts of the methanolic crude extract and fractions of *Lacistema pubescens*. In addition, their chemical profile was also evaluated. Hexane fraction showed the most significant IC_{50} values against all promastigotes of *Leishmania* species tested, except for *L. chagasi* (IC_{50} = 4.2 μ g/mL for *L. major* and IC_{50} = 3.5 μ g/mL for *L. amazonensis*). This fraction also exhibited a strong activity against amastigotes of *L. amazonensis* (IC_{50} = 6.9 μ g/mL). The antiproliferative activity was also observed for methanolic extract and hexane fraction with IC_{50} = 47.2 μ g/mL and IC_{50} = 39.7 μ g/mL for HL60, respectively. Regarding the antimicrobial activity, the overall antibacterial activity was not very significative. Phytol and sitosterol were identified in the methanolic extract. Additionally, previous studies also revealed the presence of those compounds in the hexane fraction. Among other compounds, phytol and sitosterol were probably involved in the antileishmanial and cytotoxicity activities observed in this study.

1. Introduction

The family Lacistemataceae is represented by the genera *Lacistema* and *Lozania* with about 11 and 4 species, respectively [1]. Some species of *Lacistema* are traditionally used by Brazilian indigenous from Amazon against rheumatism, vomiting, dysentery, body aches, and fever [2–4]. A list of the Peruvian Amazonian plants used for medicinal purposes also mentioned *Lacistema* sp. to combat rheumatism and as antipyretic [4]. In addition, some studies had shown the potential pharmacological properties of some *Lacistema*

species such as antiplasmodial [4], antimutagenic [5], antifungal [6], and antiviral [7].

Originally from Brazil, *Lacistema pubescens* Mart. is widely distributed in other countries such as Bolivia, Guyana, and Venezuela. In Brazil, it is known as “espeto vermelho,” “canaleta vermelha” [8, 9] “sabãozinho” [10], and “cafezinho” [11]. Recently, it was evidenced that the leaves of *L. pubescens* present a potential antioxidant capacity, possibly correlated to phenolic compounds detected in this species [12]. Also, the antinociceptive and anti-inflammatory activity of the hexane fraction of *L. pubescens* leaves were reported [13] confirming

the popular use of the genus by indigenous communities. This study also resulted in the identification of fatty acids such as palmitic acid and stearic and linoleic acid in this fraction. Tocopherol, the diterpene phytol, and the sterol sitosterol were also identified.

To the best of our knowledge, apart from those preliminary reports on the chemical composition and pharmacological activities of *L. pubescens* [12, 13], no other reports on the phytochemical or bioactivity of this species are available to date. So, the present study was conducted to evaluate the *in vitro* antibacterial, antiproliferative, and antileishmanial properties and to identify some compounds of the methanolic extract of *L. pubescens*.

2. Materials and Methods

Plant Material. *Lacistema pubescens* Mart. leaves were collected in Juiz de Fora, State of Minas Gerais, Brazil, in December 2011 and identified by Dra. Fátima Regina Gonçalves Salimena from the Department of Botany of the Institute of Biological Sciences (Federal University of Juiz de Fora). A voucher specimen (CESJ 49751) has been deposited at the Leopoldo Krieger Herbarium of the Federal University of Juiz de Fora.

Preparation of the Methanolic Extract and Fractions. The dried leaves (375 g) were powdered and macerated with methanol (5×300 mL) for five days at room temperature. The methanolic extract (57 g), after removal of solvent, was dissolved in MeOH-H₂O (8:2) and partitioned with hexane and ethyl acetate to obtain hexane (16 g), ethyl acetate (7 g), and the remaining hydromethanolic fractions (5 g). The extract and fractions were then concentrated using a rotary evaporator under reduced pressure and kept in tightly stoppered bottle under refrigeration until being used for the biological testing.

High Pressure Liquid Chromatography (HPLC) Analysis. HPLC analysis with a DAD detector and an automatic injector (Agilent Technologies 1200 Series, USA) was performed for methanolic extract, ethyl acetate, and hydromethanolic fractions. The column employed was a Zorbax SB-18; 250 $\times$ 4.6 mm, 5 μ m particle size. The mobile phase applied was 0–30 min, HPLC-grade methanol-acetonitrile (70:30 v/v). The sample volume was 20 μ L (1 mg/mL), the flow rate was 1 mL/min, and the temperature was maintained at 25°C during the analysis. Detection was performed at 210 nm. Phytol and sitosterol standards (Sigma-Aldrich, USA) were used in this experiment as markers under the same conditions used for the samples.

In Vitro Antileishmanial Activity Evaluation. *Leishmania major* (MRHO/SU/59/P), *L. braziliensis* (MHOM/BR/M2903), *L. chagasi* (MHOM/BR/PP75), and *L. amazonensis* (IFLA/BR/67/PH8) promastigotes were used for *in vitro* screening.

Antipromastigote Assays. The antileishmanial activity was determined by colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich, USA)

method [14]. Briefly, promastigotes of *L. amazonensis* were cultured in the Warren's medium (brain heart infusion plus hemin and folic acid), promastigotes of *L. braziliensis* and *L. major* were maintained in BHI medium, and promastigotes of *L. chagasi* were maintained in medium 199, both supplemented with 10% fetal bovine serum at 24°C. The screening was performed in 96-well microplates maintained at 24°C. The samples tested were added at different concentrations (100 to 6.25 μ g/mL) after dilution in water or DMSO (dimethylsulfoxide), and the highest used concentration of DMSO was 0.8% (v/v), which is not toxic to the parasites. Then, a parasite suspension from a logarithmic phase culture was suspended to yield 2 million parasites/well (*L. amazonensis*) or 3 million parasites/well (*L. chagasi*, *L. major*, and *L. braziliensis*) after Neubauer chamber counting. Controls with DMSO and without plant samples were performed. All samples were tested in triplicate, in three independent experiments. The viability of promastigotes was assayed after a three-day incubation period with addition of MTT. The reaction was stopped with HCl in isopropyl alcohol and the optical densities were evaluated in a spectrophotometer at 570 nm. The results were expressed as the concentrations inhibiting parasite growth by 50% (IC₅₀) calculated using a nonlinear regression curve, by using GraFit Version 5 software (Erithacus Software, Horley, UK). Amphotericin B (Cristalia, São Paulo, Brazil) was used as the standard drug (1.000 to 0.008 μ g/mL).

Antiamastigote Assays. Macrophages were obtained from the peritoneal cavity of BALB/c mice previously inoculated with 3% thioglycollate medium (Sigma-Aldrich, USA). Briefly, peritoneal macrophages were plated at 2×10^6 cells/mL on coverslips (13 mm diameter) previously arranged in a 24-well plate in RPMI 1640 medium supplemented with 10% inactivated FBS, and allowed to adhere for 24 h at 33°C in 5% CO₂. Adherent macrophages were infected with *L. amazonensis* (IFLA/BR/67/PH8) promastigotes in the stationary growth phase using a 1:10 ratio at 33°C for 4 h. Noninternalized promastigotes were eliminated and solutions of test compounds were added (25.0 to 1.6 μ g/mL) and maintained at 33°C 5% CO₂ for 72 h. Slides were fixed and stained with Giemsa for parasite counting (optical microscopy, 1000x magnification). The parasite burden was evaluated was evaluated comparing the number of intracellular amastigotes in treated and untreated cultures (number of amastigotes in treated group/number of amastigotes in untreated group $\times$ 100). A minimum of 200 cells were counted (infected and uninfected macrophages). Miltefosine (Cayman Chemical Company, Michigan, USA) was used as the reference drug (1.000 to 0.039 μ g/mL). All procedures were performed in agreement with the Ethical Principles in Animal Research and according to protocols approved by the Ethical Committee of for Animal Research.

For statistical analysis, the 50% inhibitory concentration, that is, the minimum compound concentration that caused 50% reduction in survival of the amastigote and promastigote forms of *Leishmania* (IC₅₀), was carried out and the 95% confidence intervals were included, calculated by Litchtfiet and Wilcoxon method using the Probit. The graphs were

plotted by the program GraphPad Prism 4 (GraphPad software, USA). The data were analyzed statistically using analysis of variance (ANOVA) followed by Dunnett post-test to compare all groups to the control group. Differences were regarded as significant when $P < 0.0001$ (***)).

Cytotoxicity against Mammalian Cells. Mouse peritoneal macrophages were plated at 2×10^6 macrophages/mL in 96-well culture plates and incubated for 72 h at 37°C in 5% CO_2 in RPMI 1640 medium containing 10% fetal bovine serum and different concentrations of the test samples (150.0 to $9.4 \mu\text{g/mL}$) in 0.5% DMSO. The viability of the macrophages was determined with the MTT assay and was confirmed by comparing the morphology of the control group via light microscopy. CC_{50} values (50% cytotoxicity concentration) were obtained by using GraFit Version 5 software. The cytotoxicity for macrophages and for amastigotes of *L. amazonensis* was compared using the selectivity index (SI), which was determined as the ratio between CC_{50} for macrophages and IC_{50} for parasites.

Cell Lines. HL60 cells (human promyelocytic leukemia HL-60 cells) and human immortalized lines of T lymphocyte (Jurkat cells) were a kind gift from Dr. Gustavo Amarante-Mendes (São Paulo University, Brazil). All lineages were cultivated in the logarithmic phase of growth in RPMI 1640 medium (Sigma-Aldrich, USA) supplemented with 100 U/mL penicillin and $100 \mu\text{g/mL}$ streptomycin enriched with 2 mM of L-glutamine and 10% of fetal bovine serum (Gibco). All cultures were maintained at 37°C in a humidified incubator with 5% CO_2 .

Cytotoxic Effect against Human Tumor Cell Lines. The leukemia cell lines were cultured in 96-well plate at densities of 50,000 cells/well, in a final volume of $200 \mu\text{L/well}$. The plates were preincubated in a 5% $\text{CO}_2/95\%$ air-humidified atmosphere at 37°C for 24 h to allow adaptation of cells prior to the addition of the samples. The test samples were dissolved in DMSO and the half maximal inhibitory concentration (IC_{50}) was determined over a range of concentrations of a freshly prepared solution of the samples (100 to $6.25 \mu\text{g/mL}$). All cell cultures were incubated in a 5% $\text{CO}_2/95\%$ air-humidified atmosphere at 37°C for 48 h. Cell viability was estimated by MTT assay [14]. The optical densities were measured with a spectrophotometer at 590 nm. Control groups included treatment with 0.1% DMSO (negative control) and etoposide $14 \mu\text{M}$ (positive control). All samples were tested in triplicate, in three independent experiments.

Antibacterial Assay. The samples were evaluated against a panel of bacteria strains, including *Staphylococcus aureus* (ATCC 6538), *Pseudomonas aeruginosa* (ATCC 15442), *Shigella dysenteriae* (ATCC 13313), *Salmonella typhimurium* (ATCC 13311), *Escherichia coli* (ATCC 10536), *Enterococcus faecalis* (ATCC 51299), and *Enterobacter cloacae* (ATCC 10699).

Serial Dilution Assay for Determination of the Minimal Inhibitory Concentration (MIC). The minimal inhibitory

concentration (MIC) of the extract and its fractions was determined by using the broth microdilution technique [15]. MIC values were determined in Mueller Hinton broth (MHB). Bacteria were cultured overnight at 37°C for 24 h in BHI. Sample stock solutions were diluted from 1000 to $7.8 \mu\text{g/mL}$ (final volume = $80 \mu\text{L}$) and a final DMSO concentration $\leq 1\%$. Then, MHB ($100 \mu\text{L}$) was added into microplates. Finally, $20 \mu\text{L}$ of 10^8 CFU/mL (according to McFarland turbidity standards) of standardized bacterial suspensions was inoculated into microplates and the test was performed at a volume of $200 \mu\text{L}$. Plates were incubated at 37°C for 24 h. The same tests were performed simultaneously for growth control (MHB + bacteria) and sterility control (MHB + extract/fractions) and as positive control, chloramphenicol at concentrations from 100 to $0.78 \mu\text{g/mL}$. MIC was calculated as the lowest concentration which shows complete inhibition of the strain tested.

3. Results and Discussion

The HPLC chromatogram profile of the methanolic extract of *L. pubescens* was performed and two compounds were identified as phytol and sitosterol (Figure 1). Those compounds were not detected in ethyl acetate and hydromethanolic fractions (data not shown). Additionally, our previous studies also revealed the presence of those compounds in the hexane fraction [13].

The methanolic extract of *L. pubescens* leaves and its fractions were tested against promastigote forms of different *Leishmania* species which are responsible for various clinical manifestations, ranging from simple cutaneous form to severe visceral form. This is a widespread disease, affecting 12 million people around the world with about 1-2 million estimated new cases occurring every year [16]. The current treatment for all forms of clinical manifestation of leishmaniasis is based on pentavalent antimonials, amphotericin B, and Pentamidine. However, they are toxic, expensive, and difficult to administer and their use induces parasite resistance [17, 18].

For all bioassay, the IC_{50} values below $100 \mu\text{g/mL}$ were considered significant [19]. As demonstrated in Table 1, the methanolic extract and hexane fraction were potent against *L. amazonensis*, with $\text{IC}_{50} = 3.9$ and $3.5 \mu\text{g/mL}$, respectively. Hexane fraction also presented strong activity for *L. major* ($\text{IC}_{50} = 4.2 \mu\text{g/mL}$), while methanolic extract was completely inactive. For *L. braziliensis*, those samples showed $\text{IC}_{50} = 17$ and $45.6 \mu\text{g/mL}$, respectively. Ethyl acetate and hydromethanolic fractions presented no antileishmanial activity. Neither the extract nor the fractions were active against *L. chagasi* promastigotes at the maximum concentration tested. Variations in sensitivity to several pure compounds and extracts against promastigotes of different *Leishmania* species have also been reported in previous studies [20–24]. Biochemical and molecular differences between *Leishmania* species including the pattern of glycosylation, enzymes as nucleotidases, and phosphomonoesterases, as well as the major lipophosphoglycan (LPG) present in surface of *Leishmania* sp., have been reported [25–27]. Comparison between the whole-genome expression patterns of *L. major*

FIGURE 1: Chromatogram of methanolic extract of *L. pubescens* leaves. Peaks identified: 1, phytol (TR = 4.8 min), and 2, sitosterol (TR = 18.5 min). HPLC conditions: Zorbax SB-18 (250 mm × 4.6 mm i.d.; 5 μ m); methanol-acetonitrile (70 : 30 v/v); 1.0 mL/min; injection volume, 20 μ L; UV detection at 210 nm.

FIGURE 2: Effect of methanolic extracts (a) and hexane fraction (b) on intracellular amastigotes. Peritoneal macrophages previously infected with *L. amazonensis* promastigotes in the stationary growth phase were exposed to the samples for 72 h. The parasite burden was evaluated comparing the number of intracellular amastigotes in treated and untreated cultures (control). All results were significant (***) $P < 0.0001$.

and *L. infantum* also showed some variations in genes involved in metabolism, cellular organization and biogenesis, transport and genes encoding unknown function [28]. Thus the variation in intrinsic sensitivity to several extracts is not surprising.

Promastigote forms of *Leishmania* were used as preliminary screening for antileishmanial activity. Subsequently, assays using amastigote forms were also performed. Intracellular amastigotes are considered the gold standard for antileishmanial *in vitro* evaluation, as this parasite forms are found in mammalian host, including the man, and are responsible for all clinical manifestations of leishmaniasis [29]. *Leishmania amazonensis*, the most sensitive *Leishmania* species in the antipromastigote tests (Table 1), was chosen for the anti-amastigote assays. In this assay, the macrophages were efficiently infected (controls = 50% of infected macrophages, with 4.3 parasites/infected cells). In general, it was observed

that the methanolic extract and hexane fraction of *L. pubescens* showed dose-dependent effect in the reduction of the number of intracellular parasites (Figure 2). Furthermore, as can be seen in Figure 2, hexane fraction showed a higher percentage of inhibition of global burden of amastigotes with 56.6, 49.7, 38.4, and 37.1% (12.5, 6.2, 3.1, and 1.6 μ g/mL, resp.). Methanolic extract also exhibited expressive activity with 75.4, 55.5, 32.3, 38.5, and 34.4% of inhibition of global burden (25.0, 12.5, 6.2, 3.1, and 1.6 μ g/mL, resp.). Furthermore, IC_{50} values for the hexane fraction and methanolic extract against *L. amazonensis* amastigotes was very low (6.9 and 8.1 μ g/mL, resp.) and highlighted the activity of those samples against intracellular form of the parasite (Table 2). Miltefosine, the reference drug, exhibited IC_{50} value of 3.9 μ g/mL.

Macrophages are the main host cell for *Leishmania* protozoa, so it is important to know the toxicity of the methanolic extract and hexane fraction of *L. pubescens* on

TABLE 1: Antileishmanial and antiproliferative activity of the methanolic extract and fractions of *L. pubescens*.

Samples	IC ₅₀ values (μg/mL) ^b				Antiproliferative activity	
	Antileishmanial activity (promastigote forms) ^a				HL60	Jurkat
	La	Lb	Lm	Lc		
Methanolic extract	3.9 (±0.7)	45.6 (±2.1)	>100	>100	47.2 (±13.08)	>100
Hexane	3.5 (±0.9)	17.0 (±0.07)	4.2 (±0.8)	>100	39.7 (±1.37)	>100
Ethyl acetate	>100	>100	>100	>100	>100	>100
Hydromethanol	>100	>100	>100	>100	>100	>100
Amphotericin B ^c	0.4 (±0.05)	0.30 (±0.09)	0.3 (±0.09)	1.9 (±0.25)	—	—
Etoposide ^d	— ^e	—	—	—	0.02 (±0.01)	3.0 (±2.13)

Organism key: ^aLa: *Leishmania amazonensis*; Lb: *Leishmania braziliensis*; Lm: *Leishmania major*; Lc: *Leishmania chagasi*.

^bIC₅₀ values (concentrations inhibiting cell growth by 50%). Data are presented as median and 95% confidence interval (in parentheses).

^{c,d}Control drug. ^eND: not done.

TABLE 2: Effect of the compounds on intracellular amastigotes of *L. amazonensis* and selectivity index.

Samples	Macrophages CC ₅₀ (μg/mL) (95% C.I.) ^a	Amastigotes CC ₅₀ (μg/mL) (95% C.I.) ^a	Selectivity index (SI) ^b
Methanolic extract	35.9 (±0.06)	8.1 (5.8–11.2)	4.4
Hexane	22.1 (±1.4)	6.9 (4.0–11.8)	3.2

^aData are IC₅₀ values in μg/mL and 95% confidence intervals are in brackets.

^bSelectivity index (SI) was calculated by dividing the CC₅₀ of macrophages by the IC₅₀ values of amastigotes of *L. amazonensis*.

these cells as well as their selectivity on the intracellular parasites. Compounds with selectivity index (SI) ≥ 1.0 were considered more destructive to amastigotes of *L. amazonensis* than to the host cells [30]. Regarding to the selectivity of the samples, it is important to be mentioned that, despite the cytotoxic effect on macrophages, methanolic extract and hexane fraction were 4.1 and 3.6 times, respectively, more destructive to amastigotes than to the host cells (Table 2).

Sitosterol was identified as one of the chemical constituents detected in methanolic extract of *L. pubescens* leaves (Figure 1) and in the hexane fraction [13]. This compound had been already shown to have antileishmanial activity by inhibiting in 70% the promastigote forms of *L. amazonensis* growth at 100 μg/mL [31]. So, there is a possibility that sitosterol may be partially responsible for the antileishmanial activity of *L. pubescens*. However, the leishmanicidal activity against promastigotes and amastigotes of *L. amazonensis* observed in this work may be also attributed to other compounds present in active samples.

Natural extracts have been previously reported as potential sources of antiproliferative compounds [32–34]. The antiproliferative activity of methanolic extract and fractions of *L. pubescens* against HL60 e Jurkat human leukemia cells

was evaluated and the results are shown in Table 1. Methanolic extract and the hexane fraction showed a moderate activity against HL60 cells while Jurkat cells were resistant to all samples tested.

Compounds like phytol and sitosterol, found in the methanolic extract and previously detected in the hexane fraction [13] may be, at least in part, responsible for the antiproliferative activity against HL60 cell line. Studies have demonstrated that sitosterol showed a highest antiproliferative activity against human tumor cells [35]. Results suggested that sitosterol induces endoreduplication by promoting spindle microtubule dynamics through the Bcl-2 and PI3 K/Akt signaling pathways [36]. Other studies have also shown the cytotoxicity of phytol on cancer cell lines as HL60 [37] which was due to induction of apoptosis [38].

Antibacterial activity of *L. pubescens* samples was evaluated by MIC determination for some bacteria commonly known to cause human infection. Results are reported in Table 3. MIC values ranged from 125 μg/mL to 1000 μg/mL. Ethyl acetate and hydromethanolic fractions showed the highest antibacterial activity against gram-negative bacteria *Enterobacter cloacae* (125 μg/mL). Therefore, the overall antibacterial activity was not very significative. Among the seven bacterial strains tested, the gram-negative bacterium *E. cloacae* was the most sensitive to the extract and fractions, while *S. aureus* and *Enterococcus faecalis* were the most resistant. Previous works have demonstrated that sitosterol is inactive for several bacteria strains as some evaluated in this study [39, 40]. Phytol was shown to inhibit the growth of *S. aureus* [41]. However this activity was not observed in this work.

4. Conclusions

The results obtained represent a worthwhile contribution to biological and chemical knowledge of a traditional medicinal

TABLE 3: Antimicrobial activity of the methanolic extract and fractions of *L. pubescens*.

Samples	MIC ^a (mg/mL)						
	SA	PA	SD	ST	EC	EN	EF
Methanolic extract	1	0.5	0.5	0.5	1	0.5	1
Hexane	1	1	0.5	0.5	1	1	1
Ethyl acetate	1	0.5	0.5	0.5	0.5	0.125	1
Hydromethanol	1	0.5	0.250	0.250	0.5	0.125	1
Chloramphenicol ^b	0.02	>0.1	0.05	0.003	0.001	0.003	0.03

Microorganisms: SA: *Staphylococcus aureus*; PA: *Pseudomonas aeruginosa*; SD: *Shigella dysenteriae*; ST: *Salmonella typhimurium*; EC: *Escherichia coli*; EN: *Enterobacter cloacae*; EF: *Enterococcus faecalis*.

^aMIC: minimum inhibitory concentration.

^bControl drug.

plant from Brazilian flora and indicated that *Lacistema pubescens* is a great candidate for further activity-guided fractionation in the search for new active therapeutic compounds.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

The authors are grateful to Fundação de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG) and Universidade Federal de Juiz de Fora (UFJF), Brazil, for financial support, to Dr. Fatima Regina Salimena for the botanical identification of species and to Delfino Antonio Campos for technical assistance.

References

- [1] United Kingdom: Lacistemataceae Holistic Database, 2008, <http://www.lacistemataceae.org/>.
- [2] L. C. Di Stasi and C. A. Hiruma-Lima, *Plantas Medicinais na Amazônia e na Mata Atlântica*, Edited by: J. H. Gutierrez, Editora UNESP, 2nd edition, 2002.
- [3] W. L. Barbosa and L. N. Pinto, "Documentação e valorização da fitoterapia tradicional Kayapó nas aldeias A'Ukre e Pykanusudeste do Pará," *Revista Brasileira de Farmacognosia*, vol. 13, pp. 47–49, 2003.
- [4] V. Roumy, G. Garcia-Pizango, A. L. Gutierrez-Choquevilca et al., "Amazonian plants from Peru used by Quechua and Mestizo to treat malaria with evaluation of their activity," *Journal of Ethnopharmacology*, vol. 112, no. 3, pp. 482–489, 2007.
- [5] M. E. Wall, M. C. Wani, T. J. Hughes, and H. Taylor, "Plant antimutagenic agents, 1. General bioassay and isolation procedures," *Journal of Natural Products*, vol. 51, no. 5, pp. 866–873, 1988.
- [6] D. G. Agripino, M. E. Lima, M. R. Silva et al., "Screening of Brazilian plants for antimicrobial and dnadamaging activities. I. Atlantic rain forest. Ecological station juréia-itatins," *Biota Neotropica*, vol. 4, pp. 1–15, 2004.
- [7] I. C. Simoni, A. P. S. Manha, L. Sciessere, V. M. H. Hoe, V. H. Takinami, and M. J. Fernandes, "Evaluation of the antiviral activity of Brazilian cerrado plants against animal viruses," *Virus Reviews & Research*, vol. 12, pp. 1–17, 2007.
- [8] N. R. S. Silva, *Florística e estrutura horizontal de uma floresta estacional semidecidual montana—mata do Juquinha de Paula, Viçosa, MG [M.S. thesis]*, Federal University of Viçosa, Viçosa, Brazil, 2002.
- [9] C. T. Silva, G. G. Reis, M. G. F. Reis, E. Silva, and R. A. Chaves, "Avaliação temporal da florística arbórea de uma floresta secundária no município de Viçosa, Minas Gerais," *Revista Árvore*, vol. 28, pp. 429–441, 2004.
- [10] F. A. P. Sobrinho, *Conhecimento etnobotânico de mateiros residentes no entorno de Unidades de Conservação no estado do Rio de Janeiro [M.S. thesis]*, Instituto de Pesquisas Jardim Botânico do Rio de Janeiro, Rio de Janeiro, Brazil, 2007.
- [11] E. F. S. Trindade, *Atributos físico-hídricos e matéria orgânica do solo em função de sistemas de uso e manejo da vegetação secundária [M.S. thesis]*, University of Amazônia, 2007.
- [12] J. M. Silva, E. V. S. Motta, R. Mendes, and E. Scio, "Caracterização fitoquímica e avaliação da capacidade antioxidante de diferentes partições de *Lacistema pubescens* Mart.," *HU Revista*, vol. 37, pp. 342–347, 2011.
- [13] J. M. da Silva, E. V. da Motta, R. F. Mendes et al., "Anti-inflammatory and antinociceptive activities of the hexane extract of *lacistema pubescens* mart. leaves," *Pharmacologyonline*, vol. 1, no. 1, pp. 9–15, 2012.
- [14] T. Mosmann, "Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays," *Journal of Immunological Methods*, vol. 65, no. 1-2, pp. 55–63, 1983.
- [15] CLSI-Manual Clinical and Laboratory Standards Institute; Twelfth informational supplement M100-512, 2002.
- [16] J. Alvar, I. D. Vélez, C. Bern et al., "Leishmaniasis worldwide and global estimates of its incidence," *PLoS ONE*, vol. 7, no. 5, Article ID e35671, 2012.
- [17] S. L. Croft and G. H. Coombs, "Leishmaniasis—current chemotherapy and recent advances in the search for novel drugs," *Trends in Parasitology*, vol. 19, no. 11, pp. 502–508, 2003.
- [18] L. Monzote, "Current treatment of leishmaniasis: a review," *The Open Antimicrobial Agents Journal*, vol. 1, pp. 9–19, 2009.
- [19] P. Cos, A. J. Vlietinck, D. V. Berghe, and L. Maes, "Anti-infective potential of natural products: how to develop a stronger in vitro "proof-of-concept"," *Journal of Ethnopharmacology*, vol. 106, no. 3, pp. 290–302, 2006.
- [20] V. A. Santos, K. M. Leite, M. Da Costa Siqueira et al., "Antiprotozoal activity of quinonemethide triterpenes from *Maytenus*

- ilicifolia* (Celastraceae)," *Molecules*, vol. 18, no. 1, pp. 1053–1062, 2013.
- [21] P. Houghton, R. Fang, I. Techatanawat, G. Steventon, P. J. Hylands, and C. C. Lee, "The sulphorhodamine (SRB) assay and other approaches to testing plant extracts and derived compounds for activities related to reputed anticancer activity," *Methods*, vol. 42, no. 4, pp. 377–387, 2007.
- [22] P. Escobar, S. Matu, C. Marques, and S. L. Croft, "Sensitivities of *Leishmania* species to hexadecylphosphocholine (miltefosine), ET-18-OCH₃ (edelfosine) and amphotericin B," *Acta Tropica*, vol. 81, no. 2, pp. 151–157, 2002.
- [23] S. L. Croft, S. Sundar, and A. H. Fairlamb, "Drug resistance in leishmaniasis," *Clinical Microbiology Reviews*, vol. 19, no. 1, pp. 111–126, 2006.
- [24] D. Sereno, A. Cordeiro da Silva, F. Mathieu-Daude, and A. Ouaisi, "Advances and perspectives in *Leishmania* cell based drug-screening procedures," *Parasitology International*, vol. 56, no. 1, pp. 3–7, 2007.
- [25] R. H. Glew, A. K. Saha, S. Das, and A. T. Remaley, "Biochemistry of the *Leishmania* species," *Microbiological Reviews*, vol. 52, no. 4, pp. 412–432, 1988.
- [26] S. M. Jeronimo and R. D. Pearson, "The *Leishmania*. Protozoans adapted for extracellular and intracellular survival," in *Subcell Biochem*, J. L. Avila and J. R. Harris, Eds., vol. 18, pp. 1–37, Plenum Press, New York, NY, USA, 1992.
- [27] I. C. Ibraim, R. R. de Assis, N. L. Pessoa et al., "Two biochemically distinct lipophosphoglycans from *Leishmania braziliensis* and *Leishmania infantum* trigger different innate immune responses in murine macrophages," *Parasites and Vectors*, vol. 6, no. 1, article 54, 2013.
- [28] A. Rochette, F. Raymond, J. Ubeda et al., "Genome-wide gene expression profiling analysis of *Leishmania major* and *Leishmania infantum* developmental stages reveals substantial differences between the two species," *BMC Genomics*, vol. 9, article 255, 2008.
- [29] M. Vermeersch, R. I. da Luz, K. Toté, J. Timmermans, P. Cos, and L. Maes, "In vitro susceptibilities of *Leishmania donovani* promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences," *Antimicrobial Agents and Chemotherapy*, vol. 53, no. 9, pp. 3855–3859, 2009.
- [30] E. S. Coimbra, L. M. R. Antinarelli, A. D. da Silva, M. L. F. Bispo, C. R. Kaiser, and M. V. N. De Souza, "7-chloro-4-quinolinyl hydrazones: a promising and potent class of antileishmanial compounds," *Chemical Biology and Drug Design*, vol. 81, no. 5, pp. 658–665, 2013.
- [31] E. C. Torres-Santos, D. Lopes, R. Rodrigues Oliveira et al., "Antileishmanial activity of isolated triterpenoids from *Pourouma guianensis*," *Phytomedicine*, vol. 11, no. 2-3, pp. 114–120, 2004.
- [32] A. M. D'Alessandro, A. Mancini, A. R. Lizzi et al., "Crocus sativus stigma extract and its major constituent crocin possess significant antiproliferative properties against human prostate cancer," *Nutrition and Cancer*, vol. 65, no. 6, pp. 930–942, 2013.
- [33] M. Deghrigue, A. Dellai, N. Akremi, V. Le Morvan, J. Robert, and A. Bouraoui, "Evaluation of antiproliferative and antioxidant activities of the organic extract and its polar fractions from the Mediterranean gorgonian *Eunicella singularis*," *Environmental Toxicology and Pharmacology*, vol. 36, no. 2, pp. 339–346, 2013.
- [34] D. Guajardo-Flores, S. O. Serna-Saldívar, and J. A. Gutiérrez-Urbe, "Evaluation of the antioxidant and antiproliferative activities of extracted saponins and flavonols from germinated black beans (*Phaseolus vulgaris* L.)," *Food Chemistry*, vol. 141, no. 2, pp. 1497–1503, 2013.
- [35] G. A. Cunha-Filho, I. S. Resck, B. C. Cavalcanti et al., "Cytotoxic profile of natural and some modified bufadienolides from toad *Rhinella schneideri* parotoid gland secretion," *Toxicon*, vol. 56, no. 3, pp. 339–348, 2010.
- [36] D. Moon, M. Kim, Y. H. Choi, and G. Kim, "β-Sitosterol induces G₂/M arrest, endoreduplication, and apoptosis through the Bcl-2 and PI₃K/Akt signaling pathways," *Cancer Letters*, vol. 264, no. 2, pp. 181–191, 2008.
- [37] S. Block, C. Baccelli, B. Tinant et al., "Diterpenes from the leaves of *Croton zambesicus*," *Phytochemistry*, vol. 65, no. 8, pp. 1165–1171, 2004.
- [38] T. Komiya, M. Kyohkon, S. Ohwaki et al., "Phytol induces programmed cell death in human lymphoid leukemia Molt 4B cells," *International Journal of Molecular Medicine*, vol. 4, no. 4, pp. 377–380, 1999.
- [39] N. R. Sanches, D. A. G. Cortez, M. S. Schiavini, C. V. Nakamura, and B. P. Dias Filho, "An evaluation of antibacterial activities of *Psidium guajava* (L.)," *Brazilian Archives of Biology and Technology*, vol. 48, no. 3, pp. 429–436, 2005.
- [40] H. Liu, K. Wang, J. Zhao, M. Wang, and L. Zhou, "Secondary metabolites from *Halostachys caspica* and their antimicrobial and antioxidant activities," *Records of Natural Products*, vol. 6, no. 1, pp. 57–61, 2012.
- [41] Y. Inoue, T. Hada, A. Shiraishi, K. Hirose, H. Hamashima, and S. Kobayashi, "Biphasic effects of geranylgeraniol, teprenone, and phytol on the growth of *Staphylococcus aureus*," *Antimicrobial Agents and Chemotherapy*, vol. 49, no. 5, pp. 1770–1774, 2005.